{"entity":{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","aka":[],"tldr":"A phase 1/2 trial of zimberelimab and sacituzumab govitecan in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.","summary":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases is a phase 1/2, interventional study registered as NCT06238921 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 31 participants, started 2024-12-19 and due to reach its primary completion in 2027-02. Interventions recorded: Stereotactic Radiation; Zimberelimab; Sacituzumab govitecan. Conditions listed: Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Triple negative breast cancer; to fulfill the requirement of triple negative disease, a breast cancer must express (≤ 10%), by immunohistochemistry (IHC), of the hormone receptors (estrogen receptor \\[ER\\] and progesterone receptor \\[PR\\])\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06238921","url":"https://clinicaltrials.gov/study/NCT06238921"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic","brain-metastases"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["zimberelimab","sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06238921","phase":"1/2","setting":"Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases (TARGET-TNBC)","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06238921/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}]}}